Trending NewsTrending NewsNASDAQ:KNSA Kiniksa Pharmaceuticals International (KNSA) Stock Price, News & Analysis $79.44 +15.91 (+25.04%) Closing price 04:00 PM EasternExtended Trading$79.90 +0.46 (+0.58%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kiniksa Pharmaceuticals International Stock (NASDAQ:KNSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KNSA alerts:Sign Up Key Stats Today's Range$67.35▼$81.9750-Day Range$46.92▼$67.2952-Week Range$29.24▼$81.97Volume2.87 million shsAverage Volume729,176 shsMarket Capitalization$6.11 billionP/E Ratio88.27Dividend YieldN/APrice Target$68.00Consensus RatingBuy Company Overview Kiniksa Pharmaceuticals International, Inc. is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies. The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome. Beyond Ilaris, Kiniksa’s clinical pipeline includes mavrilimumab, a monoclonal antibody targeting the GM-CSF receptor being investigated for giant cell arteritis; remibrutinib, a selective BTK inhibitor in Phase III studies for chronic spontaneous urticaria; and pozelimab, an anti-C5 monoclonal antibody under development for rare complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria and myasthenia gravis. Kiniksa operates globally, with commercial and development activities spanning North America, Europe and Asia under various licensing and distribution arrangements. The company is led by Founder and Chief Executive Officer John H. Johnson, who oversees a management team composed of experienced biopharmaceutical executives and scientific leaders. By combining strategic partnerships, disciplined capital allocation and a targeted R&D strategy, Kiniksa aims to deliver therapies that can transform the treatment landscape for patients with serious immune diseases.AI Generated. May Contain Errors. Read More Kiniksa Pharmaceuticals International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreKNSA MarketRank™: Kiniksa Pharmaceuticals International scored higher than 49% of companies evaluated by MarketBeat, and ranked 534th out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingKiniksa Pharmaceuticals International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and no sell ratings.Downside RiskKiniksa Pharmaceuticals International has a consensus price target of $68.00, representing about 14.4% downside from its current price of $79.44.Amount of Analyst CoverageKiniksa Pharmaceuticals International has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kiniksa Pharmaceuticals International's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth40.80% Earnings GrowthEarnings for Kiniksa Pharmaceuticals International are expected to grow by 40.80% in the coming year, from $1.25 to $1.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals International is 88.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.04.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals International is 88.27, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.30.Price to Book Value per Share RatioKiniksa Pharmaceuticals International has a P/B Ratio of 10.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kiniksa Pharmaceuticals International's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.21% of the float of Kiniksa Pharmaceuticals International has been sold short.Short Interest Ratio / Days to CoverKiniksa Pharmaceuticals International has a short interest ratio ("days to cover") of 6.85.Change versus previous monthShort interest in Kiniksa Pharmaceuticals International has recently increased by 8.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKiniksa Pharmaceuticals International does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals International does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.55 News SentimentKiniksa Pharmaceuticals International has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Kiniksa Pharmaceuticals International this week, compared to 4 articles on an average week.Search Interest5 people have searched for KNSA on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows10 people have added Kiniksa Pharmaceuticals International to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,833,228.00 in company stock.Percentage Held by Insiders51.98% of the stock of Kiniksa Pharmaceuticals International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.95% of the stock of Kiniksa Pharmaceuticals International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiniksa Pharmaceuticals International's insider trading history. Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KNSA Stock News HeadlinesKiniksa Pharmaceuticals International, plc GAAP EPS of $0.30 beats by $0.01, revenue of $243.6M beats by $17.14MJuly 28 at 7:50 AM | seekingalpha.comKiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio ExecutionJuly 28 at 7:30 AM | globenewswire.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.July 28 at 1:00 AM | Banyan Hill Publishing (Ad)Kiniksa Pharmaceuticals International, plc Q2 2026 earnings previewJuly 27 at 11:05 PM | msn.comKiniksa Pharmaceuticals International PLC (KNSA) Q2 2026: Everything You Need To Know Ahead Of ...July 27 at 1:03 PM | finance.yahoo.comKiniksa Pharmaceuticals International (KNSA) Projected to Announce Earnings on TuesdayJuly 27 at 1:56 AM | americanbankingnews.comThe Goldman Sachs Group Increases Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $75.00July 25 at 2:24 AM | americanbankingnews.comKiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026July 23, 2026 | finance.yahoo.comSee More Headlines KNSA Stock Analysis - Frequently Asked Questions How have KNSA shares performed this year? Kiniksa Pharmaceuticals International's stock was trading at $41.25 at the start of the year. Since then, KNSA shares have increased by 92.6% and is now trading at $79.44. How were Kiniksa Pharmaceuticals International's earnings last quarter? Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced its quarterly earnings data on Tuesday, July, 28th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.00. The business had revenue of $243.60 million for the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a trailing twelve-month return on equity of 13.26% and a net margin of 9.69%. Read the conference call transcript. When did Kiniksa Pharmaceuticals International IPO? Kiniksa Pharmaceuticals International (KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Kiniksa Pharmaceuticals International's major shareholders? Top institutional shareholders of Kiniksa Pharmaceuticals International include Financial Enhancement Group LLC (0.04%) and Handelsbanken Fonder AB (0.03%). Insiders that own company stock include John F Paolini, Sanj K Patel, Michael R Megna, Eben Tessari, Thomas Malley, Barry D Quart, Mark Ragosa and Ross Moat. View institutional ownership trends. How do I buy shares of Kiniksa Pharmaceuticals International? Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kiniksa Pharmaceuticals International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiniksa Pharmaceuticals International investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Today7/28/2026Last Earnings7/28/2026Next Earnings (Estimated)7/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 KNSA's financial health is in the Green zone, according to TradeSmith. KNSA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KNSA CIK1730430 Webwww.kiniksa.com Phone(781) 431-9100FaxN/AEmployees220Year Founded2015Price Target and Rating Average Price Target for Kiniksa Pharmaceuticals International$68.00 High Price Target$75.00 Low Price Target$60.00 Potential Upside/Downside-14.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$0.90 Trailing P/E Ratio88.27 Forward P/E Ratio63.55 P/E GrowthN/ANet Income$59.01 million Net Margins9.69% Pretax Margin14.06% Return on Equity13.26% Return on Assets9.86% Debt Debt-to-Equity RatioN/A Current Ratio3.79 Quick Ratio3.33 Sales & Book Value Annual Sales$754.05 million Price / Sales8.11 Cash Flow$1.00 per share Price / Cash Flow79.17 Book Value$7.44 per share Price / Book10.68Miscellaneous Outstanding Shares76,938,000Free Float36,946,000Market Cap$6.11 billion OptionableOptionable Beta0.07 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:KNSA) was last updated on 7/28/2026 by MarketBeat.com Staff. From Our Partners3 Signs of The Biggest “Melt-Up” in U.S. HistoryIn 1995, a convergence of three economic triggers fueled the biggest market melt-up in U.S. history. One self-...True Market Insiders | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThe government values gold at $42. It's really $4,800.Central banks are buying gold at the fastest pace since 1950. For the first time in 30 years, they hold more g...Golden Portfolio | SponsoredWrite This Down: A.R.M.A secretive project tied to Elon Musk, nicknamed ARM, has caught investors' attention. Musk has suggested it c...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
